公开(公告)号：US20240360239A1

公开(公告)日：2024-10-31

申请号：US18644984

申请日：2024-04-24

Applicant: Kling Biotherapeutics B.V.

Inventor： Hergen SPITS ,  Paula Maria Wilhelmina VAN HELDEN ,  Remko SCHOTTE ,  Wouter POS ,  Christien FATMAWATI ,  Danïel Michiel GO ,  Koen WAGNER ,  Julien Christian VILLAUDY

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  G01N33/574

CPC classification number: C07K16/2896 ,  A61P35/00 ,  C07K14/70596 ,  C07K16/2818 ,  G01N33/57492 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  G01N2333/70596

Abstract: The present invention provides novel binding compounds and therapeutic applications thereof.

公开(公告)号：US20240335538A1

公开(公告)日：2024-10-10

申请号：US18290668

申请日：2022-07-21

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Tae-Don KIM ,  Sooyun LEE

IPC: A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K14/73 ,  C07K14/735 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C12N5/0783

CPC classification number: A61K39/464404 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4614 ,  A61K39/4615 ,  A61K39/4631 ,  A61K39/464406 ,  A61K39/464411 ,  A61K39/464419 ,  A61K39/464429 ,  A61K39/464466 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70532 ,  C07K14/70535 ,  C07K14/7056 ,  C07K14/70575 ,  C07K14/70578 ,  C07K14/70596 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/303 ,  C07K16/32 ,  C12N5/0646 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/00

Abstract: The present invention relates to: a novel chimeric antigen receptor containing, as an intracellular signaling domain, an intracellular domain of a receptor containing a dead region; and immune cells expressing the chimeric antigen receptor. In environments in which normal cells are present, the immune cells expressing the chimeric antigen receptor according to the present invention exhibit little or no cytotoxicity and cell death of the immune cells is exhibited, thus ensuring the stability of the normal cells. Conversely, in environments in which target cells are present, the immune cells exhibit more potent cytotoxicity than with conventional techniques utilizing a lone chimeric antigen receptor.

公开(公告)号：US20240335525A1

公开(公告)日：2024-10-10

申请号：US18682372

申请日：2022-08-10

Applicant: SANOFI PASTEUR INC.

Inventor： Mario BARRO ,  Yvonne CHAN ,  Guadalupe CORTES-GARCIA ,  Raul GOMILA ,  Liqun HAN ,  Justin KLEKOTA ,  Fuqin MA ,  Satyajit RAY ,  Svetlana STEGALKINA ,  Tod STRUGNELL ,  Irina USTYUGOVA ,  Thorsten VOGEL ,  Jianxin ZHANG

IPC: A61K39/145 ,  A61K39/00 ,  A61P37/04 ,  C07K14/005 ,  C07K14/705 ,  C12N9/24

CPC classification number: A61K39/145 ,  A61P37/04 ,  C07K14/005 ,  C07K14/70596 ,  C12N9/2402 ,  C12Y302/01018 ,  A61K2039/645 ,  C07K2319/02 ,  C12N2760/16134

Abstract: Provided are modified influenza virus subtype 2 neuraminidase molecules lacking all or substantially all of the stalk region that form active, soluble tetrameric neuraminidase when expressed in host cells and vaccine compositions comprising the tetrameric neuraminidase or a nucleic acid encoding the modified monomeric influenza virus subtype 2 neuraminidase molecules that forms tetrameric NA when expressed in a cell. Also provided are methods of using the vaccine compositions to vaccinate or immunize a subject against influenza virus.

公开(公告)号：US12098173B2

公开(公告)日：2024-09-24

申请号：US17057418

申请日：2019-05-22

Applicant: The Governors of the University of Alberta

Inventor： Holger Wille ,  Jiarui Fang ,  José Miguel Flores-Fernández ,  Vineet Rathod ,  Xinli Tang

IPC: C07K14/47 ,  A61K39/00 ,  A61K39/385 ,  A61P25/16 ,  A61P25/28 ,  A61P37/04 ,  C07K14/195 ,  C07K14/285 ,  C07K14/37 ,  C07K14/705 ,  C07K16/12 ,  C07K16/14 ,  C07K16/18 ,  C07K16/28 ,  C12N9/88

CPC classification number: C07K14/47 ,  A61K39/0007 ,  A61K39/385 ,  A61P25/16 ,  A61P25/28 ,  A61P37/04 ,  C07K14/195 ,  C07K14/285 ,  C07K14/37 ,  C07K14/70596 ,  C07K16/1203 ,  C07K16/1242 ,  C07K16/14 ,  C07K16/18 ,  C07K16/2872 ,  C12N9/88 ,  C12Y402/02002 ,  A61K2039/6031 ,  A61K2039/6068 ,  C07K2319/33

Abstract: The present disclosure relates generally to polypeptides, which may be used of the treatment of neurological diseases or disorders.

公开(公告)号：US12084487B2

公开(公告)日：2024-09-10

申请号：US18357979

申请日：2023-07-24

Applicant: Emory University

Inventor： Lily Yang ,  Erica Bozeman

IPC: C07K14/705 ,  A61K31/405 ,  A61K31/4245 ,  A61K31/7088 ,  A61K38/00 ,  A61K38/17 ,  A61K38/48 ,  A61K45/06 ,  A61K47/62 ,  A61K47/69 ,  A61K49/00 ,  A61K49/18 ,  A61K51/08 ,  A61P35/02 ,  C07K14/47 ,  C07K14/78 ,  G01N33/574 ,  B82Y5/00

CPC classification number: C07K14/70521 ,  A61K31/405 ,  A61K31/4245 ,  A61K31/7088 ,  A61K38/177 ,  A61K38/482 ,  A61K38/4886 ,  A61K45/06 ,  A61K47/62 ,  A61K47/6929 ,  A61K47/6939 ,  A61K49/0002 ,  A61K49/0093 ,  A61K49/1866 ,  A61K51/08 ,  A61P35/02 ,  C07K14/70596 ,  C12Y304/21073 ,  C12Y304/2408 ,  G01N33/574 ,  B82Y5/00 ,  C07K2319/21 ,  A61K31/405 ,  A61K2300/00 ,  A61K31/4245 ,  A61K2300/00

Abstract: This disclosure relates to peptides and nanoparticles comprising a surface molecule that binds or blocks PD-L1. In certain embodiments, the disclosure relates to methods of using peptides or nanoparticles disclosed herein for the treatment of cancer. In certain embodiments, the disclosure relates to methods of using nanoparticles disclosed herein for therapeutic and diagnostic applications.

公开(公告)号：US20240284884A1

公开(公告)日：2024-08-29

申请号：US18640282

申请日：2024-04-19

Applicant: The Curators of the University of Missouri

Inventor： Randall S. Prather ,  Kevin D. Wells ,  Kristin M. Whitworth

IPC: A01K67/0276 ,  C07K14/705 ,  C12N15/85

CPC classification number: A01K67/0276 ,  C12N15/8509 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/108 ,  A01K2267/02 ,  C07K14/7056 ,  C07K14/70596

Abstract: The present invention generally relates to genetically modified swine wherein at least one allele of a SIGLEC1 gene has been inactivated and/or at least one allele of a CD163 gene has been inactivated. Genetically modified swine having both alleles of the SIGLEC1 gene and/or both alleles CD163 gene inactivated are resistant to porcine reproductive and respiratory syndrome virus (PRRSV). Methods for producing such transgenic swine are also provided.

公开(公告)号：US12070474B2

公开(公告)日：2024-08-27

申请号：US17585126

申请日：2022-01-26

Applicant: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.

Inventor： Alicja J. Copik ,  Jeremiah L. Oyer ,  Robert Y. Igarashi ,  Deborah Altomare

IPC: A61K38/20 ,  A61K35/13 ,  A61K35/17 ,  A61K38/17 ,  C07K14/54 ,  C07K14/55 ,  C07K14/705 ,  C12N5/0783 ,  A61K35/12

CPC classification number: A61K35/17 ,  A61K35/13 ,  A61K38/177 ,  A61K38/20 ,  A61K38/2013 ,  C07K14/54 ,  C07K14/5434 ,  C07K14/55 ,  C07K14/70525 ,  C07K14/70596 ,  C12N5/0646 ,  A61K2035/124 ,  C12N2500/84 ,  C12N2501/2302 ,  C12N2501/2321 ,  C12N2501/599

Abstract: Disclosed herein are novel compositions and methods for stimulation of and the production or expansion of natural killer (NK) cells. Numbers of NK cells can be increased following contact with exosomes modified with one or more stimulatory peptides. Methods and compositions for the production of exosomes, wherein the exosomes comprises stimulatory peptides are also described. Also described are methods of treating cancer using the disclosed NK-stimulating exosomes or NK cells stimulated by the disclosed methods.

公开(公告)号：US20240277763A1

公开(公告)日：2024-08-22

申请号：US18395996

申请日：2023-12-26

Applicant: ALLOGENE THERAPEUTICS, INC.

Inventor： Thomas Charles PERTEL ,  Barbra Johnson SASU ,  Mark W. LEONARD

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K16/28 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61P35/00 ,  C07K14/70517 ,  C07K14/70596 ,  C07K16/2803 ,  C12N5/0636 ,  A61K2039/505 ,  C07K2317/76 ,  C07K2319/33 ,  C12N2510/00 ,  C12N2740/15043

Abstract: Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically birnds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using these CD19-specific CARs, and immune cells comprising these CD19-specific CARs.

公开(公告)号：US12042531B2

公开(公告)日：2024-07-23

申请号：US17451607

申请日：2021-10-20

Applicant: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION

Inventor： Mary L. Disis ,  Denise Cecil ,  Meredith Slota

IPC: C12N15/00 ,  A61K39/00 ,  C07K14/47 ,  C07K14/705 ,  C07K14/71 ,  C12N9/10 ,  C12N15/62 ,  A61K48/00

CPC classification number: A61K39/0011 ,  A61K39/001103 ,  A61K39/001106 ,  A61K39/001129 ,  A61K39/00115 ,  A61K39/001152 ,  C07K14/4702 ,  C07K14/705 ,  C07K14/70567 ,  C07K14/70596 ,  C07K14/71 ,  C12N9/104 ,  C12N15/62 ,  C12Y203/02 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/572 ,  A61K48/00

Abstract: The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof.

公开(公告)号：US12036240B2

公开(公告)日：2024-07-16

申请号：US16442348

申请日：2019-06-14

Applicant: The Broad Institute, Inc. ,  Massachusetts Institute of Technology ,  The Brigham and Women's Hospital, Inc.

Inventor： Aviv Regev ,  Ana Carrizosa Anderson ,  Ayshwarya Subramanian ,  Orit Rozenblatt-Rosen

IPC: C12N5/00 ,  A61K35/17 ,  C07K14/705 ,  C07K14/725 ,  G01N33/50 ,  C07K16/28

CPC classification number: A61K35/17 ,  C07K14/7051 ,  C07K14/70596 ,  C07K16/2818 ,  C07K16/2827

Abstract: This invention relates generally to compositions and methods for modulating complement component 3 (C3) activity or expression to treat, control or otherwise influence tumors and tissues, including cells and cell types of the tumors and tissues, and malignant, microenvironmental, or immunologic states of the tumor cells and tissues. The invention also relates to methods of diagnosing, prognosing and/or staging of tumors, tissues and cells.